Financial Performance - Net profit attributable to shareholders rose by 95.56% to CNY 40,858,735.41 for the reporting period[8] - Operating revenue for the period reached CNY 128,323,860.88, reflecting a growth of 73.91% year-on-year[8] - Basic earnings per share increased by 46.68% to CNY 0.3714[8] - The net profit after deducting non-recurring gains and losses was CNY 37,702,464.57, an increase of 89.44% year-on-year[8] - The company reported a net profit increase, leading to an increase in undistributed profits by 105.80% to ¥154,345,172.88[16] - The net profit for the third quarter reached CNY 40,858,735.41, up from CNY 21,012,436.89 in the same period last year, representing an increase of approximately 94.5%[36] - The total profit for the third quarter was CNY 46,963,399.24, compared to CNY 26,143,107.62 in the previous year, reflecting an increase of approximately 79.5%[35] - The company's total profit for Q3 2018 was CNY 107,891,639.02, compared to CNY 61,839,115.99 in the same period last year, reflecting a growth of 74.5%[43] Revenue and Costs - Total operating revenue for Q3 2018 reached CNY 128,323,860.88, a significant increase of 73.8% compared to CNY 73,787,398.47 in the same period last year[33] - Total operating costs for the same period were CNY 85,098,192.60, up from CNY 49,271,525.06, reflecting a year-over-year increase of 72.7%[33] - The total operating revenue for the third quarter was CNY 149,508,564.47, compared to CNY 72,929,325.72 in the previous period, indicating a significant increase[38] - The total operating costs for the third quarter were CNY 83,515,793.76, compared to CNY 28,909,918.68 in the previous year, indicating a significant rise[38] Assets and Liabilities - Total assets increased by 14.84% to CNY 651,575,267.59 compared to the end of the previous year[8] - The company's total assets increased to CNY 681,228,045.08, up from CNY 563,909,540.12, representing a growth of 20.8%[32] - Total liabilities rose to CNY 94,534,022.40, compared to CNY 57,958,438.41, indicating an increase of 63.1%[32] - The equity attributable to shareholders reached CNY 586,694,022.68, up from CNY 505,951,101.71, marking an increase of 15.9%[32] Cash Flow - Cash flow from operating activities for the year-to-date was CNY 89,145,846.49, up 75.17%[8] - Cash inflow from operating activities totaled CNY 371,560,529.60 in Q3 2018, compared to 219,724,473.55 in the previous year, representing a growth of 68.8%[48] - The cash inflow from sales of goods and services was 331,550,514.61, up from 193,592,384.44 in the previous period, representing an increase of approximately 71%[53] - The cash outflow from financing activities amounted to 23,983,622.36, compared to 4,028,304.30 in the previous period, indicating a substantial increase[54] Research and Development - Research and development expenses increased by 71.27% to ¥28,463,244.49, indicating a significant investment in innovation[17] - Research and development expenses for the quarter amounted to CNY 10,166,612.14, which is an increase of 74.1% compared to CNY 5,836,844.66 in the previous year[33] - Research and development expenses for Q3 2018 amounted to CNY 23,889,234.82, up from CNY 13,049,294.93 in the previous year, indicating a 83.5% increase[46] Shareholder Information - The company reported a total of 10,275 common shareholders at the end of the reporting period[12] - The top shareholder, Yang Minmin, holds 22.22% of the shares, amounting to 24,442,023 shares[12] Tax and Other Financial Metrics - The tax payable increased by 220.37% to ¥10,047,968.73, reflecting higher profits and corresponding tax liabilities[16] - The company reported a tax expense of CNY 12,741,028.34 for Q3 2018, compared to CNY 9,059,364.75 in the previous year, which is an increase of 40.5%[43] - The total comprehensive income for the third quarter was CNY 42,316,316.42, compared to CNY 20,964,203.77 in the previous year, showing an increase of approximately 101.1%[36]

Financial Performance - Total revenue for the first half of 2018 reached ¥210,798,266.43, representing a 72.83% increase compared to ¥121,971,133.37 in the same period last year[18]. - Net profit attributable to shareholders was ¥53,156,706.58, up 67.45% from ¥31,744,651.00 year-on-year[18]. - Basic earnings per share increased by 73.88% to ¥0.6691, compared to ¥0.3848 in the same period last year[18]. - The net profit after deducting non-recurring gains and losses was ¥48,282,438.20, reflecting a 51.86% increase from ¥31,794,613.76 in the previous year[18]. - The gross profit margin for the period was 56.06%, with a net profit attributable to shareholders of 48.28 million yuan, an increase of 51.86% compared to the same period last year[36]. - The company achieved a revenue of 210.80 million yuan, representing a year-on-year growth of 72.83%[36]. - The company reported a total non-operating income of 4,874,268.38, with government subsidies contributing 2,561,849.00 and investment income from entrusted asset management at 3,164,027.40[22]. - The company reported a net profit for the first half of 2018 of CNY 54,291,875.27, compared to CNY 31,767,314.36 in the previous year, marking an increase of about 70.8%[148]. - The company's operating profit was CNY 58,267,433.33, up from CNY 35,017,257.83 in the same period last year, reflecting a growth of approximately 66.5%[147]. Cash Flow and Investments - Net cash flow from operating activities surged by 292.07% to ¥68,901,807.09, compared to ¥17,574,053.21 in the previous year[18]. - The cash flow from operating activities for the first half of 2018 was CNY 247,409,854.58, significantly higher than CNY 118,772,457.38 in the same period of 2017[154]. - The net cash flow from investment activities was -CNY 100,780,201.00, worsening from -CNY 21,408,010.44 in the previous period[156]. - The company received CNY 340,000,000.00 from investment recoveries, a significant increase from CNY 1,000,000.00 in the previous period[159]. - The company reported a net cash increase of -¥53,748,026.50, a 387.87% increase in cash outflow compared to -¥11,016,835.77, primarily due to increased investments in bank financial products[57]. Assets and Liabilities - Total assets as of June 30, 2018, were ¥610,480,964.91, a 7.59% increase from ¥567,395,667.52 at the end of the previous year[18]. - Total liabilities increased to CNY 91,077,497.02, up from CNY 63,801,245.19, indicating a rise of around 42.5%[139]. - Owner's equity reached CNY 519,403,467.89, compared to CNY 503,594,422.33, showing a growth of about 3.1%[140]. - The company’s cash and cash equivalents decreased to ¥103,814,444.26 from ¥157,562,470.76, representing a decline of approximately 34.2%[137]. - The company reported a decrease in cash and cash equivalents to CNY 87,576,614.30 from CNY 141,910,412.68, a decline of approximately 38.3%[142]. Research and Development - The company focuses on the design, research, and commercialization of drug molecular building blocks, aiming to enhance drug development efficiency and success rates[25]. - The company has developed a library of over 40,000 unique drug molecular building blocks, with more than 4,000 of them not reported in literature[38]. - Research and development expenses rose by 69.69% to ¥18,296,632.35, compared to ¥10,782,088.51, reflecting the company's commitment to technological innovation[57]. - The company has established advanced process chemistry technologies, including flow chemistry and biocatalysis, to enhance drug development efficiency and reduce costs[36]. - The enzyme chemistry team has built a library of over 300 types of enzymes, enabling successful implementation of various enzymatic reactions[53]. Market and Sales - The company’s overseas sales accounted for over 70% of total sales, maintaining strong relationships with major global pharmaceutical companies[39]. - The sales model includes direct sales and distribution partnerships, with a focus on maintaining a comprehensive library of drug molecular building blocks to meet market demands[32]. - The company anticipates increased demand for kilogram-level and ton-level orders as client projects progress, leading to significant revenue growth[35]. - The company actively participates in industry conferences to showcase its capabilities and gather market intelligence, enhancing its competitive edge[32]. Risks and Challenges - The company faces risks including slowing performance growth and declining gross margins, which investors should be aware of[4]. - The company has identified risks related to the slowdown in client drug development projects, which could limit revenue growth if clients' projects progress slowly[81]. - The company plans to enhance sales channels and strengthen customer relationships to mitigate risks associated with performance growth slowdown[80]. Corporate Governance and Structure - The company has not distributed cash dividends or issued bonus shares[5]. - The company has not engaged in any major litigation or arbitration matters during the reporting period[92]. - The company has not undergone any bankruptcy restructuring during the reporting period[91]. - The company has not reported any issues or abnormalities in the usage, disclosure, or storage of raised funds[70]. - The company has a total of 36,666,667 shares that were converted from capital reserves, which is a significant portion of the total shares[116]. Shareholder Information - Major shareholders include Yang Minmin with a 22.22% stake, holding 24,442,023 shares, and Wu Xihan with a 7.57% stake, holding 8,331,720 shares[119]. - The total number of ordinary shareholders at the end of the reporting period was 11,284[119]. - The number of restricted shares increased from 55,000,000 to 82,500,000, with an increase of 27,500,000 shares, maintaining a 75% proportion[116]. Compliance and Reporting - The financial report was approved for release on August 27, 2018, indicating the reporting period's end[174]. - The company adheres to the accounting standards, ensuring that the financial statements accurately reflect the financial position as of June 30, 2018, and the operating results and cash flows for the first half of 2018[180]. - The company uses RMB as its functional currency for accounting purposes[183].

Financial Performance - Total revenue for Q1 2018 reached ¥99,240,994.02, an increase of 86.79% compared to ¥53,128,637.96 in the same period last year[7] - Net profit attributable to shareholders was ¥20,081,573.12, up 59.32% from ¥12,604,529.82 year-on-year[7] - Net profit excluding non-recurring items was ¥18,131,000.87, reflecting a 39.75% increase from ¥12,961,513.19 in the previous year[7] - Basic earnings per share increased to ¥0.27, a rise of 17.39% from ¥0.23[7] - The company reported a net profit of ¥4,465,766.71, a 58.92% increase in income tax expenses due to higher operating income[18] - The net profit for the first quarter was CNY 21,201,725.34, up 74.0% from CNY 12,196,571.94 year-over-year[43] - The operating profit for the quarter was CNY 24,597,607.62, which is an increase of 67.8% from CNY 14,682,102.58 year-over-year[43] Cash Flow - The net cash flow from operating activities was ¥23,503,993.38, a significant recovery from a negative cash flow of ¥1,070,566.93 in the same period last year[7] - Total cash inflow from operating activities amounted to ¥127,365,568.89, up from ¥53,951,113.22 in the prior period, indicating a growth of approximately 135%[50] - Cash outflow from operating activities totaled ¥103,861,575.51, compared to ¥55,021,680.15 in the previous period, reflecting an increase of about 88.8%[50] - The net cash flow from investing activities was -¥48,319,698.52, worsening from -¥8,666,305.06 in the prior period[51] - The net cash flow from financing activities was -¥5,015,969.26, slightly improved from -¥5,272,233.19 in the previous period[51] Assets and Liabilities - Total assets at the end of the reporting period were ¥575,628,288.65, a 1.45% increase from ¥567,395,667.52 at the end of the previous year[7] - The total current liabilities decreased to CNY 42,035,899.27 from CNY 54,514,138.36, a decline of approximately 22.8%[36] - The total liabilities decreased significantly, with short-term borrowings dropping to zero from ¥298,988.13, as the company repaid credit card expenses[17] - The company's total liabilities decreased to CNY 53,145,165.59 from CNY 57,958,438.41, a reduction of 8.5%[43] Operational Efficiency - The company's gross profit margin for Q1 2018 was 58.40%, down from 62.12% in Q1 2017, indicating potential risks in maintaining competitive advantages[9] - The company's gross profit margin was impacted by a 135.67% increase in operating costs, which rose to ¥41,288,694.87 from ¥17,519,654.06[17] - Management expenses rose by 77.15% to ¥28,367,786.26, reflecting increased investment in R&D and higher employee compensation[17] - The gross profit margin for the quarter was approximately 24.5%, compared to 30.0% in the same quarter last year[43] Shareholder Information - The total number of shareholders at the end of the reporting period was 13,415, with the top shareholder holding 22.22% of the shares[12] - The company did not engage in any repurchase transactions among its top shareholders during the reporting period[14] - The top five customers accounted for 51.86% of total sales, up from 39.60% in the same period last year[21] - The top five suppliers' procurement amount was ¥7,634,397.69, which constituted 17.07% of total procurement, down from 27.09% year-over-year[20] Investment and R&D - The company plans to increase R&D investment to maintain its competitive edge and mitigate risks associated with declining gross margins[9] - The company plans to continue enhancing its product technology and R&D capabilities to strengthen its competitive position in the global pharmaceutical market[20] - The company has invested a total of ¥1,110.68 million from the raised funds, which is 6.08% of the total planned investment of ¥18,272.4 million[26] - The company has utilized ¥1,419.04 million of raised funds to replace self-raised funds previously invested in projects[27] Risk Management - The company has not experienced significant changes in major risk factors or operational difficulties during the reporting period[23] - The company maintains a strong focus on innovation in drug development and aims to capitalize on growth opportunities in emerging pharmaceutical markets[20]

Financial Performance - The company's operating revenue for 2017 was ¥273,250,557.29, representing a 45.05% increase compared to ¥188,377,858.27 in 2016[15]. - The net profit attributable to shareholders for 2017 was ¥67,179,202.18, an increase of 86.01% from ¥36,115,206.60 in 2016[15]. - The net cash flow from operating activities reached ¥54,639,657.83, showing a significant increase of 140.09% compared to ¥22,757,688.70 in 2016[15]. - The basic earnings per share for 2017 was ¥1.19, up 72.46% from ¥0.69 in 2016[15]. - Total assets at the end of 2017 amounted to ¥567,395,667.52, a growth of 89.67% from ¥299,148,882.65 at the end of 2016[15]. - The net assets attributable to shareholders increased by 101.90% to ¥495,255,420.67 from ¥245,300,638.90 in 2016[15]. - The weighted average return on equity for 2017 was 22.84%, an increase from 21.18% in 2016[15]. - The gross profit margin for the reporting period was 62.12%[34]. - The comprehensive gross profit margin for 2017 was 62.12%, a slight decrease from 66.36% in 2016, indicating potential risks of margin compression as the company scales[86]. Dividend Policy - The company plans to distribute a cash dividend of ¥2.00 per 10 shares, with a capital reserve conversion of 5 shares for every 10 shares held[4]. - The cash dividend for the year is set at 2.00 CNY per 10 shares, with a total cash dividend amounting to approximately 14.67 million CNY, representing 100% of the profit distribution[96]. - The proposed cash dividend for 2017 is RMB 2 per 10 shares, totaling RMB 14,666,666.80, which represents 21.83% of the net profit attributable to shareholders[100]. - The company has maintained a consistent approach to profit distribution, with a focus on balancing immediate shareholder returns and long-term business needs[97]. - The cash dividend distribution for 2017 marks the first cash dividend since the company's IPO, reflecting a positive shift in financial performance[100]. Research and Development - The company specializes in the research and development of small molecule drugs, providing innovative chemical products and related technical services[25]. - The company has developed a diverse library of drug molecular building blocks, which are crucial for new drug development, and offers custom research and development services[30]. - The company’s research and development efforts are supported by access to multiple authoritative databases, enhancing its ability to innovate[30]. - The company has a strong focus on expanding its drug molecular building block library to meet the diverse needs of its clients[30]. - Research and development expenses for 2017 totaled ¥24,731,700, representing 9.05% of total sales revenue[64]. - The number of R&D personnel increased to 58 in 2017, accounting for 13.58% of total employees, up from 11.49% in 2016[65]. - The company is focused on increasing R&D investment to maintain its competitive edge in technology and products, aiming to safeguard profitability amidst industry challenges[86]. Market Presence and Sales - The company’s overseas sales account for over 70% of total sales, indicating a strong international market presence[37]. - The company’s accounts receivable increased by 38.97%, reflecting the growth in operating revenue as product volumes increased[39]. - The company has established long-term strategic partnerships with influential clients, including major multinational pharmaceutical companies such as Novartis and Merck KGaA[37]. - The company achieved an operating revenue of approximately 273.25 million yuan in 2017, representing a year-on-year growth of about 45.05%[47]. - The company has seen a significant increase in orders for kilogram-level and ten-kilogram-level products, leading to larger single order amounts and increased sales revenue[34]. Risks and Challenges - The company faces risks including slowing performance growth and declining gross margins, which investors should be aware of[4]. - The company recognizes the risk of sales growth being affected by the progress of clients' drug development projects, emphasizing the need to ensure quality supply and explore existing customer demands[87]. - The company plans to expand sales channels and strengthen customer relationships to mitigate risks associated with potential slowdowns in drug development investments by clients[86]. Corporate Governance and Compliance - The company has committed to fulfilling its obligations regarding shareholder returns while ensuring sustainable business growth[100]. - The company has committed to ensuring that the prospectus does not contain false records, misleading statements, or major omissions, and assumes legal responsibility for its authenticity, accuracy, completeness, and timeliness[141]. - The company has not engaged in any major related party transactions during the reporting period[152]. - The company has not reported any significant changes in the shareholding structure of its major shareholders during the reporting period[188]. - The company has maintained a stable management team with no changes in key executive positions during the reporting period[192]. Future Outlook - The company provided guidance for the next fiscal year, projecting a revenue growth of 20% to reach approximately 1.8 billion RMB[111]. - The company is exploring potential mergers and acquisitions to bolster its market position and expand its capabilities[200]. - The company plans to focus on key customers to establish long-term partnerships and enhance sales efforts[84]. - The company intends to leverage new equipment to enhance production processes for its catalog products and support CDMO and generic drug businesses[84].